Blinatumomab Induces High MRD Response Rate in ALL
Published: Tuesday, Feb 06, 2018
Nicola Gökbuget, MD
Nearly 80% of patients assigned to blinatumomab (Blincyto) for minimal residual disease (MRD)-positive acute lymphoblastic leukemia (ALL) in hematologic complete remission (CR) achieved complete MRD response, according to results from a phase II study.
... to read the full story